148 related articles for article (PubMed ID: 1997044)
41. Limited phase I study of morphine-3-glucuronide.
Penson RT; Joel SP; Clark S; Gloyne A; Slevin ML
J Pharm Sci; 2001 Nov; 90(11):1810-6. PubMed ID: 11745739
[TBL] [Abstract][Full Text] [Related]
42. Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.
Stain-Texier F; Boschi G; Sandouk P; Scherrmann JM
Br J Pharmacol; 1999 Oct; 128(4):917-24. PubMed ID: 10556926
[TBL] [Abstract][Full Text] [Related]
43. The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram.
Laizure SC; Miller JH; Stevens RC; Donahue DJ; Laster RE; Brown D
Pharmacotherapy; 1993; 13(5):471-5. PubMed ID: 8247914
[TBL] [Abstract][Full Text] [Related]
44. Preliminary study of the pharmacokinetics, tissue distribution, and behavioral and select physiological effects of morphine 6-glucuronide (M6G) following intravenous administration to horses.
Hamamoto-Hardman BD; Steffey EP; Seminoff K; McKemie DS; Kass P; Knych HK
Can J Vet Res; 2022 Jul; 86(3):172-180. PubMed ID: 35794968
[TBL] [Abstract][Full Text] [Related]
45. Comparative measurement of spinal CSF microdialysate concentrations and concomitant antinociception of morphine and morphine-6beta-glucuronide in rats.
Okura T; Komiyama N; Morita Y; Kimura M; Deguchi Y; Yamada S
Life Sci; 2007 Mar; 80(14):1319-26. PubMed ID: 17258777
[TBL] [Abstract][Full Text] [Related]
46. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
Milne RW; McLean CF; Mather LE; Nation RL; Runciman WB; Rutten AJ; Somogyi AA
Drug Metab Dispos; 1995 Mar; 23(3):334-42. PubMed ID: 7628298
[TBL] [Abstract][Full Text] [Related]
47. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine.
Wu D; Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1997 Jun; 25(6):768-71. PubMed ID: 9193881
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of morphine-6-glucuronide (M6G) for postoperative pain relief: a randomized, double-blind study.
Smith TW; Binning AR; Dahan A
Eur J Pain; 2009 Mar; 13(3):293-9. PubMed ID: 18550399
[TBL] [Abstract][Full Text] [Related]
49. Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study.
Illum L; Davis SS; Pawula M; Fisher AN; Barrett DA; Farraj NF; Shaw PN
Biopharm Drug Dispos; 1996 Nov; 17(8):717-24. PubMed ID: 8950049
[TBL] [Abstract][Full Text] [Related]
50. A randomized, double-blind, placebo-controlled pilot study of IV morphine-6-glucuronide for postoperative pain relief after knee replacement surgery.
Romberg R; van Dorp E; Hollander J; Kruit M; Binning A; Smith T; Dahan A
Clin J Pain; 2007; 23(3):197-203. PubMed ID: 17314577
[TBL] [Abstract][Full Text] [Related]
51. Morphine-6-glucuronide: effects on ventilation in normal volunteers.
Peat SJ; Hanna MH; Woodham M; Knibb AA; Ponte J
Pain; 1991 Apr; 45(1):101-104. PubMed ID: 1907362
[TBL] [Abstract][Full Text] [Related]
52. Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites.
Sear JW; Hand CW; Moore RA; McQuay HJ
Br J Anaesth; 1989 Jan; 62(1):22-7. PubMed ID: 2917110
[TBL] [Abstract][Full Text] [Related]
53. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
54. Toxicity and pharmacokinetics of morphine and morphine-6-glucuronide.
Br J Anaesth; 1991 Sep; 67(3):362-3. PubMed ID: 1911031
[No Abstract] [Full Text] [Related]
55. Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients.
Sear JW; Hand CW; Moore RA
J Clin Anesth; 1989; 1(3):164-9. PubMed ID: 2627383
[TBL] [Abstract][Full Text] [Related]
56. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Drewe J; Ball HA; Beglinger C; Peng B; Kemmler A; Schächinger H; Haefeli WE
Br J Clin Pharmacol; 2000 Sep; 50(3):237-46. PubMed ID: 10971308
[TBL] [Abstract][Full Text] [Related]
57. A randomised controlled trial on the efficacy and side-effect profile (nausea/vomiting/sedation) of morphine-6-glucuronide versus morphine for post-operative pain relief after major abdominal surgery.
Binning AR; Przesmycki K; Sowinski P; Morrison LM; Smith TW; Marcus P; Lees JP; Dahan A
Eur J Pain; 2011 Apr; 15(4):402-8. PubMed ID: 21041105
[TBL] [Abstract][Full Text] [Related]
58. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity.
Babul N; Darke AC
Clin Pharmacol Ther; 1993 Sep; 54(3):286-92. PubMed ID: 8375123
[TBL] [Abstract][Full Text] [Related]
59. Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.
Morrish GA; Foster DJ; Somogyi AA
Br J Clin Pharmacol; 2006 Mar; 61(3):326-35. PubMed ID: 16487227
[TBL] [Abstract][Full Text] [Related]
60. [Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high performance liquid chromatography and colorimetric detection].
Barberi-Heyob M; Merlin JL; Krakowski I; Kettani C; Collin E; Poulain P
Bull Cancer; 1991 Nov; 78(11):1063-70. PubMed ID: 1369552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
